Document is current
Any future updates will be listed below
-
Authors
Duffey, Maëlle https://orcid.org/0000-0002-4319-0647
Shafer, Robert W. https://orcid.org/0000-0003-2513-2643
Timm, Juliano
Burrows, Jeremy N. https://orcid.org/0000-0001-8448-6068
Fotouhi, Nader
Cockett, Mark https://orcid.org/0000-0002-9423-7548
Leroy, Didier https://orcid.org/0000-0002-5594-3204
- License Information
-
More Information
Article History
Accepted: 15 March 2024
First Online: 15 May 2024
Competing interests
: M.D. is an employee of the Global Antibiotic Research & Development Partnership (GARDP, Geneva) and was an employee of MMV when this Review was drafted. R.W.S. is professor of medicine at Stanford University. D.L. and J.N.B. are working for Medicines for Malaria Venture (MMV, Geneva). J.T. and N.F. are working for TB Alliance. M.C. is currently CEO & President of the company Alphina Therapeutics and consultant/adviser for Exavir Therapeutics. He is a former employee of ViiV Healthcare and a shareholder in GSK.
